Twist Bioscience's Q1 2025 Earnings: A Beacon of Growth in Synthetic Biology
Generated by AI AgentMarcus Lee
Tuesday, Feb 4, 2025 12:57 am ET1min read
TWST--
Twist Bioscience Corp. (TWST), a leading player in the synthetic biology and genomics space, recently reported its first quarter fiscal 2025 earnings, providing investors with a glimpse into the company's strong financial performance and growth prospects. The South San Francisco-based company reported a loss of $31.6 million, or 53 cents per share, for the quarter, surpassing Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 62 cents per share. Twist Bioscience's revenue of $88.7 million also exceeded Street forecasts, with four analysts surveyed by Zacks expecting $86.9 million.
Twist Bioscience Corp. (TWST), a leading player in the synthetic biology and genomics space, recently reported its first quarter fiscal 2025 earnings, providing investors with a glimpse into the company's strong financial performance and growth prospects. The South San Francisco-based company reported a loss of $31.6 million, or 53 cents per share, for the quarter, surpassing Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 62 cents per share. Twist Bioscience's revenue of $88.7 million also exceeded Street forecasts, with four analysts surveyed by Zacks expecting $86.9 million.
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet